Psychedelics & Cannabis

Phase 2b data show DT‑120, optimized oral LSD, delivers durable GAD remission with mostly same‑day side effects; phase 3 trials advance.

Phase 3 data show COMP360 psilocybin rapidly lifts treatment-resistant depression, with durable MADRS gains and stronger effects from 2 sessions.

Experts discuss ketamine safety, monitoring, neurotoxicity concerns, and key considerations for psychiatrists treating depression at the ASCP Annual Meeting.

How ketamine enhances psychotherapy—and what new psilocybin studies suggest about broader health effects.

Federal fast-tracks boost psychedelic research.

How FDA priority review vouchers speed psychedelic therapy approvals.

New psychiatry drugs target dementia agitation, ADHD, depression, TRD, and schizophrenia—see which novel mechanisms may reach the FDA next.

New cohort and global data link teen high-potency cannabis use to higher psychosis, bipolar, and suicide risks. Here's what psychiatrists and mental health clinicians should know in the era of legalization.

In the wake of the FDA fast-track of psychedelic therapies, we want to hear your clinical pearls for our May theme.

The triple-blinded EPISODE trial with active placebo and 4 dosing regimens yielded mixed results, reflecting the challenge of discerning psilocybin effect and distinguishing between enlightenment and expectation.

Read our exclusive interview with Daniel R. Karlin, MD, MA, on the latest executive order, DT120 for the treatment of mental health disorders, and more.

DT120, a pharmaceutical-grade formulation of LSD, shows rapid, lasting anxiety relief—single dose, no therapy—with 48% remission at 12 weeks.

FDA accelerates psychedelic drug development to advance agents for TRD, PTSD, and AUD.

Definium’s CMO says FDA talks stay aligned with their plans for advancing DT120 ODT for the treatment of depression, anxiety, and now PTSD.

Psychedelic therapies surge, but a rushed FDA shortcut risks safety; learn why ibogaine claims need rigorous trials and oversight.

High-potency cannabis surges; psychiatry confronts psychosis risk, dependence, and data gaps—why clinicians must guide safer use now.

A new US-based grant program seeks to create training content for health care providers who want to be able to deliver investigational COMP360 psilocybin treatment.

Guy Goodwin, MD, provides insights into COMP360 psilocybin and recent trial results, as well as psychedelics as a whole and their role in psychiatry.

Compass Pathways reports COMP360 psilocybin shows fast, durable relief in treatment‑resistant depression. Guy Goodwin, MD, shares his insights.

An expert shares why new kratom variants have dangerous implications for substance use disorder.

Data show fast-acting psychedelic therapy for depression with lasting gains—plus the safety questions shaping its future.

See why ketamine boosts outcomes for treatment‑resistant depression.

Discover more on the uses and context of ketamine.

Learn more about developments in COMP360 and psychedelic news.

Psilocybin for depression nears approval; clinicians must manage medication interactions, avoiding lithium and MAOIs while monitoring vital signs and blunted effects.